News

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.

Prevent Blindness has declared May the second annual inherited retinal disease and genetic testing month, offering free resources on education and other awareness efforts.

A large international study reported a genetic link between schizophrenia and retinal status.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy.

A two-way foot bridge between eye care and mental health.

Brazilian researchers used swept-source OCT and OCT-angiography to study the effects of an initial dose of aflibercept on untreated diabetic macular edema in patients.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

Novel color created, olo, beyond previous human perception.

Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.

Marsh will begin her role as COO April 28.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Phase I/II safety and efficacy study currently enrolling.

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission.

This agreement allows a launch in the US in the second half of 2026 or earlier in certain circumstances.

Congenital ectopia lentis is a rare ocular disease characterized by the dislocation or displacement of the lens.

Eyecyte-RPE is a suspension of human induced pluripotent stem cells derived from retinal pigment epithelial cells.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts.

Nau will lead the company in a new phase of growth and innovation.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).